Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon beta-1a - Merck Serono

Drug Profile

Interferon beta-1a - Merck Serono

Alternative Names: r-IFNβ-1a; Rebif; Rebif Rebidose; Rebif® modified formulation; Rebif® New Formulation; Rebif® reformulation; Rebif® Serum-free formulation; Recombinant human interferon beta-1a; RNF - Merck Serono; scIFN β 1a

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Weizmann Institute of Science
  • Developer EMD Serono; Merck Serono
  • Class Antineoplastics; Interferons
  • Mechanism of Action Immunostimulants; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple sclerosis
  • No development reported Hepatitis C; Human papillomavirus infections; Non-small cell lung cancer; Ulcerative colitis
  • Discontinued Crohn's disease; Rheumatoid arthritis

Most Recent Events

  • 31 Dec 2014 Biomarkers information updated
  • 06 May 2014 EMD Serono plans a phase IV RESOunD trial for Multiple Sclerosis in USA (NCT02117050)
  • 01 Sep 2013 Merck completes the global phase III REFLEXION extension trial for Multiple sclerosis (NCT00813709)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top